Ignite Creation Date:
2024-05-06 @ 11:03 AM
Last Modification Date:
2024-10-26 @ 12:39 PM
Study NCT ID:
NCT03423199
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-22
First Post:
2018-01-09
Brief Title:
PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive HER2-negative Advanced Breast Cancer Women - Asian studY
Sponsor:
National Cancer Center Japan
Organization:
National Cancer Center Japan
Study Overview
Official Title:
Asian International Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Trial of Tamoxifen With or Without Palbociclib Goserelin in Women With Hormone Receptor-Positive HER2-Negative Advanced or Metastatic Breast Cancer
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PATHWAY
Brief Summary:
This study is conducted to evaluate the benefit of adding palbociclib in hormone receptor HR-positive HER2-negative advanced or metastatic breast cancer patients regardless of menopausal status treated with tamoxifen with or without goserelin versus tamoxifen alone with or without goserelin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| WI217662 | OTHER | Pfizer | None |